Home > Research > Publications & Outputs > Comparison of the risk of hospitalisation among...

Research

Links

Text available via DOI:

View graph of relations

Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England. / Harman, Katie; Nash, Sophie Grace; Webster, Harriet H. et al.
In: Influenza and Other Respiratory Viruses, Vol. 17, No. 5, e13150, 28.05.2023.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Harman, K, Nash, SG, Webster, HH, Groves, N, Hardstaff, J, Bridgen, J, Blomquist, PB, Hope, R, Ashano, E, Myers, R, Rokadiya, S, Hopkins, S, Brown, CS, Chand, M, Dabrera, G & Thelwall, S 2023, 'Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England', Influenza and Other Respiratory Viruses, vol. 17, no. 5, e13150. https://doi.org/10.1111/irv.13150

APA

Harman, K., Nash, S. G., Webster, H. H., Groves, N., Hardstaff, J., Bridgen, J., Blomquist, P. B., Hope, R., Ashano, E., Myers, R., Rokadiya, S., Hopkins, S., Brown, C. S., Chand, M., Dabrera, G., & Thelwall, S. (2023). Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England. Influenza and Other Respiratory Viruses, 17(5), Article e13150. https://doi.org/10.1111/irv.13150

Vancouver

Harman K, Nash SG, Webster HH, Groves N, Hardstaff J, Bridgen J et al. Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England. Influenza and Other Respiratory Viruses. 2023 May 28;17(5):e13150. doi: 10.1111/irv.13150

Author

Harman, Katie ; Nash, Sophie Grace ; Webster, Harriet H. et al. / Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England. In: Influenza and Other Respiratory Viruses. 2023 ; Vol. 17, No. 5.

Bibtex

@article{106aa5e7b9eb4111bbdbfcadbf6507a5,
title = "Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England",
abstract = "There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub-lineage of the Omicron SARS-CoV-2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2 days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74–1.86). These results suggest that the risk of hospital admission was similar between the two sub-lineages.",
author = "Katie Harman and Nash, {Sophie Grace} and Webster, {Harriet H.} and Natalie Groves and Jo Hardstaff and Jessica Bridgen and Blomquist, {Paula B.} and Russell Hope and Efejiro Ashano and Richard Myers and Sakib Rokadiya and Susan Hopkins and Brown, {Colin S.} and Meera Chand and Gavin Dabrera and Simon Thelwall",
year = "2023",
month = may,
day = "28",
doi = "10.1111/irv.13150",
language = "English",
volume = "17",
journal = "Influenza and Other Respiratory Viruses",
issn = "1750-2640",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England

AU - Harman, Katie

AU - Nash, Sophie Grace

AU - Webster, Harriet H.

AU - Groves, Natalie

AU - Hardstaff, Jo

AU - Bridgen, Jessica

AU - Blomquist, Paula B.

AU - Hope, Russell

AU - Ashano, Efejiro

AU - Myers, Richard

AU - Rokadiya, Sakib

AU - Hopkins, Susan

AU - Brown, Colin S.

AU - Chand, Meera

AU - Dabrera, Gavin

AU - Thelwall, Simon

PY - 2023/5/28

Y1 - 2023/5/28

N2 - There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub-lineage of the Omicron SARS-CoV-2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2 days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74–1.86). These results suggest that the risk of hospital admission was similar between the two sub-lineages.

AB - There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub-lineage of the Omicron SARS-CoV-2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2 days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74–1.86). These results suggest that the risk of hospital admission was similar between the two sub-lineages.

U2 - 10.1111/irv.13150

DO - 10.1111/irv.13150

M3 - Journal article

VL - 17

JO - Influenza and Other Respiratory Viruses

JF - Influenza and Other Respiratory Viruses

SN - 1750-2640

IS - 5

M1 - e13150

ER -